Immunoglobulin (IG) replacement therapy has served as lifesaving treatment in primary
immunodeficiency diseases (PID) for more than six decades. Approximately 70% of patients …

Intravenous immunoglobulin (IVIg) use is growing dramatically internationally due to the
increasing numbers of acute and chronic conditions that may benefit from IVIg. Patients with …

The use of immunoglobulin (Ig) preparations (intravenous, IVIg, subcutaneous, SCIg) for
replacement and immunomodulation therapy worldwide has tripled in the past 20 years and …

Intravenous immunoglobulin (IVIG) is a first-line drug prepared from human plasma for the
treatment of autoimmune diseases (AIDs), especially immune thrombocytopenia (ITP) …

Aim Intravenous immunoglobulin (IVIG) is an expensive therapy used in immunodeficiency
and autoimmune disorders. Increasing demands and consequent shortages result in a need …

Introduction: The objective of this retrospective study was to describe the short‐and long‐
term patterns of IVIg use, safety, and response to treatment in patients with chronic …

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease of
the peripheral nervous system, in which both cellular and humoral immune responses are …

To compare the effect of IV immune globulin (IVIG) and anti‐D globulin (anti‐D) for treatment
of immune thrombocytopenia (ITP) in children. A randomized, open‐label, single‐center …

Background Intravenous immunoglobulin (IVIG) replacement therapy is increasingly in
demand. This study focused on the characteristics of IVIG usage and associated factors …

Background: Administration of intravenous immunoglobulins (IVIgs) is established for long-
term treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) …